Targeting the TSH receptor in thyroid cancer

Area of Science:

• Oncology
• Endocrinology
• Theranostics

Background:

• The established use of thyroid-stimulating hormone receptor (TSHR) targeting in differentiated thyroid cancer management involves levothyroxine and recombinant human thyroid-stimulating hormone (TSH).
• Personalized medicine necessitates a deeper understanding of the molecular basis and individual patient benefits of TSHR targeting, especially considering risks of prolonged hyperthyroidism.

Purpose of the Study:

• To re-examine the role of TSHR targeting in light of theranostic advancements.
• To evaluate TSHR as a potential target for residual metastatic thyroid cancer.
• To review the evidence for TSHR signaling in oncogenesis and its expression in metastatic thyroid cancer.

Main Methods:

• Literature review of existing research on TSHR targeting in thyroid cancer.
• Analysis of pilot data on nanoparticle targeting via TSHR.
• Assessment of TSHR signaling pathways and expression in metastatic disease.

Main Results:

• TSHR is a well-understood target in post-surgical differentiated thyroid cancer management.
• Emerging evidence suggests TSHR as a viable target for metastatic thyroid cancer, with successful nanoparticle delivery shown in pilot studies.
• TSHR signaling is implicated as an oncogenic pathway, and its expression persists in thyroid cancer metastases.

Conclusions:

• A comprehensive understanding of TSHR's molecular basis and individual patient benefits is crucial for personalized thyroid cancer therapy.
• TSHR represents a promising therapeutic target for metastatic thyroid cancer, warranting further investigation.
• Further research is needed to elucidate the full potential of TSHR-targeted therapies and diagnostics.